Combined treatment with subcutaneous interferon-α, oral isoprinosine, and lamivudine for subacute sclerosing panencephalitis

Journal of Child Neurology

Volumn 18, Issue 2, 2003, Pages 104-108

  Faruk Aydin, Ömer ^a   Şenbil, Nesrin ^a   Kuyucu, Necdet ^b   Gürer, Y K Yavuz ^a  

^a DR SAMI ULUS CHILDREN S HOSPITAL   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IBUPROFEN; LAMIVUDINE; METHISOPRINOL; RECOMBINANT ALPHA2A INTERFERON;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD MORTALITY; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; EMOTIONAL DISORDER; FAMILY; FEMALE; FEVER; HUMAN; IRRITABILITY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUBACUTE SCLEROSING PANENCEPHALITIS; SURVIVAL RATE;

EID: 0037305456     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738030180020701     Document Type: Article

References (40)

1. Anlar B: Subacute sclerosing panencephalitis: Diagnosis and drug treatment options. CNS Drugs 1997;7:11-120.
2. Anlar B, Köse G, Gürer Y, et al: Changing epidemiological features of subacute sclerosing panencephalitis. Infection 2001;29:192-195.
3. Hutchins S, Markowitz L, Atkinson W, et al: Measles outbreaks in the United States, 1987 through 1990. Pediatr Infect Dis J 1996;15:31-38.
4. Risk W, Haddad F: The variable natural history of subacute sclerosing panencephalitis: A study of 118 cases from the Middle East. Arch Neurol 1979;36:610-614.
5. Yalaz K, Anlar B, Oktem F, et al: Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992;42:488-491.
6. Gascon G, Yamani S, Crowell J, et al: Combined oral isoprinosine-intraventricular α-IFN therapy for subacute sclerosing panencephalitis. Brain Dev 1993;15:346-355.
7. Gürer YK, Kükner Ş, Sarica B: Intravenous γ-globulin treatment in a patient with subacute sclerosing panencephalitis. Pediatr Neurol 1996;14:72-74.
8. Al Rajeh S, Kabiraj MM, Al Fawaz I, et al: Can cytotoxic drugs cure subacute sclerosing panencephalitis?, letter. Lancet 1995;346:377.
9. Haslam RH, McQuillen MP, Clark DB: Amantadine therapy in subacute sclerosing panencephalitis. A preliminary report. Neurology 1969;11:080-1086.
10. Robertson WC Jr, Clark DB, Markesbery WR: Review of 38 cases of subacute sclerosing panencephalitis: Effect of amantadine on the natural course of the disease. Ann Neurol 1980;8:422-425.
11. Hosoya M, Shigeta S, Nakamura K, De Clerq E: Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in vitro. Antiviral Res 1989;12:87-97.
12. Ogle JW, Toltzis P, Parker WD, et al: Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis 1989;159:748-750.
13. Tomoda A, Shiraishi S, Hosoya M, et al: Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis. Pediatr Neurol 2001;24:54-59.
14. Hosoya M, Shigeta S, Mori S, et al: High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2001;45:943-945.
15. Takahashi T, Hosoya M, Kimura K, et al: The cooperative effect of interferon-alpha and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in vitro and in vivo. Antiviral Res 1998;37:29-35.
16. Durant RH, Dyken PR, Swift A: The influence of inosiplex treatment on the neurological disability of patients with subacute panencephalitis. J Pediatr 1982;101:288-293.
17. Ohnishi H, Kosuzume H, Inaba H, et al: The immunomodulatory action of inosiplex in relation to its effects in experimental viral infections. Int J Immunopharmacol 1983;5:181-196.
18. Huttenlocher PR, Mattson RH: Isoprinosine in subacute sclerosing panencephalitis. Neurology 1979;29:763-771.
19. Kuroki S, Tsutsui T, Yoshioka M, et al. The effect of intraventricular interferon on subacute sclerosing panencephalitis. Brain Dev 1989;11:65-69.
20. Norris FH, Panitch HS, Denys EH, et al: The treatment of subacute sclerosing panencephalitis with interferon: A case report. J Neurol 1986;233:102-107.
21. Peters M: Mechanisms of action of interferons. Semin Liver Dis 1989;9:235-239.
22. Peters M: Actions of cytokines on the immune response and viral interactions: An overview. Hepatology 1996;23:900-916.
23. Gadoth N, Kott E, Levin S, et al: The interferon system in SSPE and its response to isoprinosine. Brain Dev 1989;11:308-312.
24. Wills RJ: Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990;19:390-399.
25. Tsai SL, Liaw YF, Chen MH, et al: Detection of type-2 like T helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity. Hepatology 1997;25:449-458.
26. Anlar B, Soylemezoglu F, Aysun S, et al: Tissue inflammatory response in subacute sclerosing panencephalitis (SSPE). J Child Neurol 2001;16:895-900.
27. Inoue T, Kira R, Nakao F, et al: Contribution of the interleukin 4 gene to susceptibility to subacute sclerosing panencephalitis. Arch Neurol 2002;59:822-827.
28. Anlar B, Yalaz K, Imir T, Turanli G: The effect of inosiplex in subacute sclerosing panencephalitis: A clinical and laboratory study. Eur Neurol 1994;34:44-47.
29. Anlar B, Gucuyener K, Imir T, et al: Cimetidine as an immunomodulator in subacute sclerosing panencephalitis: A double blind, placebo-controlled study. Pediatr Infect Dis J 1993;12:578-581.
30. Ishii T, Hosoya M, Mori S, et al: Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother 1996;40:241-243.
31. Balfour HH: Antiviral drugs. N Engl J Med 1999;340:1255-1267.
32. Chongsrisawat V, Poovorawan Y: Management of chronic hepatitis B and C virus infections. Indian J Pediatr 2002;69:149-154.
33. Ishii K, Tanaka Y, Yap CC, et al: Expression of hepatitis C virus NS5B protein: Characterization of its RNA polymerase activity and RNA binding. Hepatology 1999;29:1227-1235.
34. Patterson JB, Cornu TI, Redwine J, et al: Evidence that the hypermutated M protein of a subacute sclerosing panencephalitis measles virus actively contributes to the chronic progressive CNS disease. Virology 2001;291:215-225.
35. Sidhu MS, Crowly J, Lowenthal A, et al: Defective measles virus in human subacute sclerosing panencephalitis brain. Virology 1994;202:631-641.
36. van Leeuwen R, Katlama C, Kitchen V, et al: Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A phase I/II study. J Infect Dis 1995;171:1166-1171.
37. Risk WS, Haddad FS, Chemali R: Substantial spontaneous longterm improvement in subacute sclerosing panencephalitis: Six cases from the Middle East and a review of the literature. Arch Neurol 1978;35:494-502.
38. Dyken PR, Swift A, DuRant RH: Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex. Ann Neurol 1982;11:359-364.
39. Yamani SA, Gascon GG, Cook JD, et al: Combined intraventricular alpha interferon-oral isoprinosine treatment of subacute sclerosing panencephalitis (SSPE), abstract. Neurology 1991;41(Suppl 1):202.
40. Sone S, Maeda K, Haginoya K, et al: A clinical trial of interferon therapy in a case of rapidly progressive SSPE. Brain Dev 1986;8:636-640.